Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446253 | 0.94 | SLC29A1 (0.49) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL474592 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL10159392 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL10265714 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL12621455 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL23880678 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL14853791 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL12658368 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL19537371 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL12939575 | 0.84 | P2RY2 (0.62) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354524-B2 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120065387-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7982030-B2 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100137573-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7592446-B2 | Useful in structural determinations, particularly by X-ray crystallographic techniques; useful as food supplements | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20030055016-A1 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-03-20 | — | — | US | disclosed |
| WO-2002077002-A2 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055016-A1 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | SELENOI, NT5C3B, RNGTT | SLC29A1 39/4885SLC28A1 46/4885SLC28A2 47/4885 |
| US-20100137573-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | SELENOI, RNGTT, NT5C3B | SLC29A1 30/4885SLC28A1 36/4885SLC28A2 47/4885 |
| US-20120065387-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | SELENOI, RNGTT, NT5C3B | SLC29A1 30/4885SLC28A1 36/4885SLC28A2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.